The role of RAS in evasion of antitumor immunity by increasing the expression of immune checkpoint molecules has been less well studied, yet PD‐L1 and B7‐H3 are highly expressed in cancers harboring RAS mutations and associated with poor survival prognosis. The gene discussed is CD276; the disease is cancer.